Evaluating Haplo-HSCT for Elderly Patients with Acute Leukemia or Myelodysplastic Syndrome

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the efficacy of a reduced-intensity conditioning (RIC) regimen for haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) in elderly patients aged 55 to 70 with acute leukemia or myelodysplastic syndromes. The study focuses on patients who do not have HLA-matched donors but have access to haploidentical donors. Primary endpoints include one-year leukemia-free survival, while secondary endpoints will evaluate overall survival and transplant-related mortality, among other factors. The study seeks to improve transplant tolerability and outcomes for this vulnerable patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients ≥55 years of age and \<70 years of age, with acute leukemia or MDS (with or without HCT-CI≥3);
* Patients eligible for the transplantation of allogeneic hematopoietic stem cells;
* Patients unavailable with HLA matched donors but available with haploidentical donors;
* Voluntary participation in this study and signing the informed consent form.

Exclusion Criteria:

* Patients with the severe infections;
* Pregnant or lactating women or female and male subjects of childbearing age and their spouses who are unable to secure effective contraception during the dosing period and within 90 days after the end of the dosing period.
* Patients who are not eligible for hematopoietic stem cell transplantation;
* Patients who are enrolled in other clinical trials within 1 month;
* Patients who may not be able to complete the study for other reasons, or may be considered by the investigator not suitable to participate in the study;
* Patients unable to properly understand or refusing to accept the informed consent form.

Where it's running

• Peking University People's Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Sun
• Email: sunyuqian83@hotmail.com
• Phone: 01088326666

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Reduced-intensity donor stem cell transplant with treosulfan/fludarabine and post-transplant cyclophosphamide for leukemia and MDS

  This trial tests a lower-intensity donor stem cell transplant using treosulfan plus fludarabine with post-transplant cyclophosphamide to try to reduce toxicity and prevent graft-versus-host disease in people aged 2–75 with acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 2 Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota · NCT07493538

• Two-step ATG to prevent GVHD after myeloablative allogeneic stem cell transplant

  This study tests whether a two-step dosing of rabbit ATG added to tacrolimus and low-dose methotrexate can help prevent severe acute and chronic GVHD in adults 18–60 receiving myeloablative allogeneic peripheral blood stem cell transplants for leukemia, MDS, or myeloproliferative disorders.

  Recruiting Phase 2 University of Alabama at Birmingham · Birmingham, Alabama · NCT06315309

• Using CD45RA Depleted Stem Cells to Improve Immune Recovery After Transplant

  This study is testing if using special stem cells can help patients with acute leukemia recover their immune system faster after a transplant and reduce the risk of complications.

  Recruiting Children's Hospital of Philadelphia · Philadelphia, Pennsylvania · NCT03810196

• Transplanting umbilical cord blood from unrelated donors

  This study is testing different ways to prepare patients for umbilical cord blood stem cell transplants to see how safe and effective the procedure is for them.

  Recruiting University of Rochester · Rochester, New York · NCT03016806

• Menin inhibitors in pediatric relapsed or refractory acute leukemia

  This study looks at kids with relapsed or treatment-resistant acute leukemia who have specific genetic changes and are treated with menin inhibitors to see how they fare.

  Recruiting University Hospital, Strasbourg, France · Strasbourg · NCT07898436

• Artistic and movement activities to help anxiety in kids with ALL

  Kids aged 8–13 with acute lymphoblastic leukemia test whether a 16-session art and movement program can reduce anxiety compared with standard care.

  Recruiting Phase 3 Children's Cancer Hospital Egypt 57357 · Cairo, Cairo Governorate · NCT07878065

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.